BNP PARIBAS ARBITRAGE/PUT/ELI LILLY & CO/850/0.01/20.12.24 | Market Closed - Borsa Italiana 04:04:59 2024-07-12 pm EDT | ||
| 0.317 EUR | -9.94% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.323 | -8.24% |
| 24-07-11 | 0.352 | +1.15% |
| 24-07-10 | 0.348 | -1.97% |
| 24-07-09 | 0.355 | -10.80% |
| 24-07-08 | 0.398 | -2.93% |
Real-time Borsa Italiana
Last update July 12, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P253E2 | |
| ISIN | NLBNPIT253E2 |
| Date issued | 2024-07-03 |
| Strike | 850 $ |
| Maturity | 2024-12-20 (160 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.52 € |
|---|---|
| Lowest since issue | 0.313 € |
| Spread | 0.03 € |
| Spread % | 9.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Warrants
- P253E2 Warrant
